GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Short Percentage of Float

Arctic Bioscience AS (OSL:ABS) Short Percentage of Float


View and export this data going back to 2021. Start your Free Trial

What is Arctic Bioscience AS Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Arctic Bioscience AS's Short Percentage of Float

For the Biotechnology subindustry, Arctic Bioscience AS's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arctic Bioscience AS's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arctic Bioscience AS's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Arctic Bioscience AS's Short Percentage of Float falls into.


;
;

Arctic Bioscience AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arctic Bioscience AS (OSL:ABS) » Definitions » Short Percentage of Float
Comparable Companies
OSL:BGBIO OSL:PCIB OSL:CRNA OSL:EXTX OSL:SOFTX OSL:ONCIN OSL:ABTEC OSL:ZLNA VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX SMMT RPRX
Traded in Other Exchanges
9TD:Germany
Address
Industrivegen 42, Orsta, NOR, 6155
Website
https://www.arctic-bioscience.com
Arctic Bioscience AS is a clinical-stage biotechnology company working to develop drug candidates within the areas of autoimmune and inflammatory diseases. It is developing pharmaceutical and commercializing nutraceutical products based on bioactive marine compounds, including lipids essential to maintaining cell membranes. The company's proprietary extraction technology is used to extract membrane fats from marine raw materials, such as herring roe and algae. The company is developing a novel, oral drug candidate (HRO350) for the treatment of mild-to-moderate psoriasis. The company operates geographically in Norway, Americas, Europe, and APAC, with majority of the revenue deriving from Europe.

Arctic Bioscience AS Headlines

No Headlines